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Helicobacter pylori infection is found wordwide and constitutes a public health concern in many countries. Previous epidemiological studies have shown a high prevalence of H. pylori infection in 
Sicily [1] fig. 1. Antibiotic resistance is the main factor affecting efficacy of current therapeutic regimens. Prevalence of bacterial resistance varies in different geographic areas, and it has been 
correlated with the consumption of antibiotic. Particularly in Southern European countries where Clarithromycin is largely used. Clarithromycin is an integral part of first-line therapies to treat H. 
pylori infection and the resistance to this antibiotic among H. pylori isolates is accepted as a main explanation of treatment failure [2]. 
The current European guidelines on H. pylori management suggest that first-line therapy should be tailored according to Clarithromycin resistance and should be advised where primary resistance 
is > 15-20% [3]. 
Resistance of H. pylori to Clarithromycin is mainly due transition at position A2142G and A2143G and to transversion at point A2142G, which are included in the peptidyltransferase loop of the 23S 
rRNA. 
Other mutations, such as A2115G, G2141A, C2147G, T2190C, C2195T, A2223G and C2694A might, also be associated with Clarithromycin resistance [4]. 
Although H. pylori from individual patients typically have either an antibiotic susceptible or resistant phenotype, both antibiotic susceptible and resistant H. pylori (i.e. heteroresistance) have been 
reported. Heteroresistance can represent infection with a single strain harbouring two different copies of 23S rRNA gene or infection with several different H. pylori strains[5]. 
INTRODUCTION 
Patients and H. pylori strains 
Clinical H. pylori strains were isolated from patients who visited at Endoscopy Services 
of the Ospedali Civili Riuniti in Sciacca (Agrigento), A.O.U.P. Paolo Giaccone in 
Palermo and M. Raimondi Hospital,  San Cataldo (CL). 
One bioptic sample was taken from the antrum and body of each patient for cultural 
analysis. The bioptic specimens were cultured on Columbia agar (Oxoid, Basingstoke, 
Hampshire, UK) with the addition of 7% horse blood and 0.4% Dent supplement 
(Oxoid). The plates were incubated at 37°C under microaerobic conditions (CampyGen; 
Oxoid) for 3–6 days.  
Clinical H. pylori strains were identified by Gram staining urease, oxidase, and catalase 
tests. 
Susceptibility tests 
For in vitro susceptibility testing of the H. pylori strains to Clarithromycin, a 
suspension equal to McFarland tube no. 4 was prepared for each isolate. Mueller 
Hinton agar (Oxoid), with 5% of sheep-blood, was used as culture medium for 
determining antibiotic susceptibility and was inoculated by confluent swabbing of the 
surface with the adjusted inoculum suspensions, zone size breakpoint was read after 3 
days and confirmed after 5 days under microaerophilic incubation [6]. 
DNA Extraction and determination of point mutation in 23s rRNA 
Genomic content of bacteria was extracted from a fresh culture using Roche DNA kit 
according to manufacturer’s instruction. 
We confirmed our H. pylori identity with Nested PCR assay for ureaseA gene 
amplification. 
Presence of point mutations in 23S rRNA were analyzed by amplification and 
sequenced using the kit "ABI PRISM BigDye Terminator Cycle Sequencing Ready 
Reaction" (Applied Biosystems) and specific primers [4]. 
Random Amplified Polymorphic DNA (RAPD)-PCR Amplification 
One hundred nanograms of template DNA of heteroresistance strains were used for 
each RAPD-PCR reaction. 
The PCR-amplified fingerprinting patterns were visualized by ethidiumbromide staining 
under a short-wavelength ultraviolet light source [5]. 
 METHODS 
The assessment of Clarithromycin susceptibility, evaluated by Kirby-Bauer test, shows that 75% of H. pylori 
strains are susceptible, 25 % are resistant and 3% are heteroresistant, fig.2. 
To confirm the high prevalence of resistance to Clarithromycin, sequence analysis of the 23S rRNA gene have 
been carried out and a strong association between the presence of 23S rRNA gene mutation and macrolide 
resistance have been founded.  
The predominant mutation among the 25 H. pylori Clarithromycin-resistant strains is at A2143G in 80% of 
cases, while mutation A2142G is founded in 20% of cases, fig. 3.  
However point mutations C2195T and T2182C are found in 5% cases of H. pylori Clarithromycin-susceptible 
strains. 
The development of resistance, detected in the period from January 2000 to June 2011,  is changed, fig. 4. 
Individual colonies of the heteroresistance strains have been studied phenotypically and molecularly. In 
particular, a mutation in position A2142G is founded in resistant strains, whereas no mutation is present in 
sensitive strains. 
The difference between resistant and sensitive strains isolated from the same patient, has been highlighted by 
the RAPD PCR, as it is apparent from the profile shown in fig. 5.  
RESULTS  
Clarithromycin is the most important antibiotic included in all standard triple therapies for H. pylori eradication established worldwide.  
Resistance to macrolide is a main cause of treatment failure in each eradication therapy, while its prevalence varies geographically, from Western to Eastern.  
Our results demonstrate an high percentage (25%) of resistant to Clarithromycin bacterial strains. Resistance percentages found in Sicily are higher than those reported 
from other Italian regions, 16,6%[7], but lower when compared to those founded in other countries such as France, 26% [8], and Spain, 35% [9].   
However the percentages found in our region have changed over the years. The percentages of resistance, which were clearly on the rise, following the directives issued 
guidelines defined in Maastricht, have been attenuated, certainly correlated to a controlled use of the drug. Guidelines discourage use of Clarithromycin in areas where 
resistance rates are more than 15-20%. In our region, unfortunately, still today, the resistance, although declining (from 35% in 2008 to 23% in 2011), remain over the 
threshold value. Also De Francesco et al.,  reported than  in Italy, Clarithromycin resistance is present in near 10% of bacterial isolates, and it was >15% in only 3 Italian 
regions, begins as high as 25% in Sicily [9]. 
Clarithromycin resistance in H. pylori mainly results from point mutations in the peptidyltrasferase loop region of the 23SrRNA. In our study, the most frequent point of 
the mutation is  founded at position A2143G, present in 80% of cases; while A2142G is founded in only 20% of cases. This mutation predominates in H. pylori strains 
isolated from Europe and also from Japan.  
Furthermore the strong association between resistance to macrolides and specific mutations in the 23S rRNA gene is confirmed in 100% of  cases [10].  
Recent report indicated that other mutations might be also associated with claritromycin resistance; in 5% of our strains we found the mutation at the point T2182C and 
C2195T but not associated with resistance [11]. 
Finally, we found a different profile RAPD PCR on sensitive and resistant strains isolated from the same patient, correlated with a case of co-infection with different 
strains. This result suggests a stable association between different strains in persistent infections [4]. 
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Fig. n°1 Prevalence of H. pylori infection in Sicily  
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Fig n°2. Prevalence of resistance to Clarithromycin   
               of  H. pylori strains isolated in Sicily 
Fig n°3. Percentage of the most frequent 23S  
              rRNA gene point  mutation  of the 
              Sicilian H.pylori strains. 
 Fig n°4. Change in resistance rates of the H. p.   
                strains isolated from 2000 to 2011 
Fig n°5. RAPD PCR of two H. p. 
              strains, sensitive (lines 1-5)   
              and resistant (lines 6-10), 
              M ladder 100bp,  
              C negative control 
